• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perioperative management of pancreatic cancer.

作者信息

Heinemann V, Boeck S

机构信息

Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany.

出版信息

Ann Oncol. 2008 Sep;19 Suppl 7:vii273-8. doi: 10.1093/annonc/mdn450.

DOI:10.1093/annonc/mdn450
PMID:18790965
Abstract
摘要

相似文献

1
Perioperative management of pancreatic cancer.胰腺癌的围手术期管理
Ann Oncol. 2008 Sep;19 Suppl 7:vii273-8. doi: 10.1093/annonc/mdn450.
2
Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?可切除边缘性胰腺癌的围手术期治疗：是什么以及何时进行？
Ann Surg Oncol. 2019 Jun;26(6):1596-1597. doi: 10.1245/s10434-019-07177-2. Epub 2019 Jan 24.
3
Adjuvant and neoadjuvant therapy for pancreatic cancer.胰腺癌的辅助治疗和新辅助治疗
Oncology (Williston Park). 2011 Feb;25(2):192-3.
4
[Neoadjuvant chemotherapy for resectable pancreatic cancer].[可切除胰腺癌的新辅助化疗]
Nihon Shokakibyo Gakkai Zasshi. 2020;117(4):297-301. doi: 10.11405/nisshoshi.117.297.
5
Perioperative Chemotherapy for Pancreas Cancer: Quo Vadis?胰腺癌围手术期化疗：何去何从？
Ann Surg Oncol. 2024 Jul;31(7):4176-4178. doi: 10.1245/s10434-024-15257-1. Epub 2024 Apr 23.
6
[Postoperative adjuvant chemotherapy for resectable pancreatic cancer].[可切除胰腺癌的术后辅助化疗]
Nihon Shokakibyo Gakkai Zasshi. 2020;117(4):308-312. doi: 10.11405/nisshoshi.117.308.
7
Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.用于治疗可手术切除胰腺癌的辅助和新辅助治疗方法。
Curr Treat Options Oncol. 2006 Sep;7(5):381-8. doi: 10.1007/s11864-006-0006-9.
8
Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.可手术切除胰腺癌的围手术期治疗
Hematol Oncol Clin North Am. 2015 Aug;29(4):717-26. doi: 10.1016/j.hoc.2015.04.011. Epub 2015 May 30.
9
Role of adjuvant therapy in the management of pancreatic cancer.辅助治疗在胰腺癌管理中的作用。
Adv Surg. 2005;39:223-44. doi: 10.1016/j.yasu.2005.05.003.
10
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.围手术期化疗与胰头早期腺癌的生存优势相关。
Surgery. 2016 Sep;160(3):714-24. doi: 10.1016/j.surg.2016.05.029. Epub 2016 Jul 12.

引用本文的文献

1
missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.错义特异性转录可塑性驱动胰腺癌对细胞周期抑制剂的抗性。
Sci Adv. 2025 Jul 4;11(27):eadu2339. doi: 10.1126/sciadv.adu2339.
2
Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer?对于接受胰腺癌根治性胰十二指肠切除术的患者，局部治疗对肝转移是否具有潜在的肿瘤学作用？
Yonsei Med J. 2025 Jun;66(6):329-336. doi: 10.3349/ymj.2024.0078.
3
Laparoscopic pancreatectomies for borderline tumors with major venous resections.
腹腔镜下对伴有主要静脉切除的临界肿瘤进行胰腺切除术。
Wideochir Inne Tech Maloinwazyjne. 2022 Dec;17(4):680-687. doi: 10.5114/wiitm.2022.116705. Epub 2022 Sep 7.
4
Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX.接受新辅助FOLFIRINOX治疗的可切除边缘和局部晚期胰腺癌患者的适当辅助治疗。
Front Oncol. 2022 Sep 20;12:945829. doi: 10.3389/fonc.2022.945829. eCollection 2022.
5
Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis.胰腺导管腺癌伴肝转移行切除手术的生存获益：一项倾向评分匹配的监测、流行病学与结果（SEER）数据库分析
Cancers (Basel). 2021 Dec 23;14(1):57. doi: 10.3390/cancers14010057.
6
A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma.一种新型铁死亡相关基因特征可预测胰腺导管腺癌患者的复发情况。
Front Mol Biosci. 2021 Sep 23;8:650264. doi: 10.3389/fmolb.2021.650264. eCollection 2021.
7
Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer.切除修复交叉互补组6基因多态性与亚洲胰腺癌患者对FOLFIRINOX化疗的反应相关。
Cancers (Basel). 2021 Mar 10;13(6):1196. doi: 10.3390/cancers13061196.
8
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.接受新辅助FOLFIRINOX治疗的可切除边缘或局部晚期胰腺癌患者的预后因素
Gut Liver. 2021 Mar 15;15(2):315-323. doi: 10.5009/gnl19182.
9
Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics.用于胰腺癌治疗诊断的 Y 型标记组织因子单克隆抗体
Mol Pharm. 2020 May 4;17(5):1697-1705. doi: 10.1021/acs.molpharmaceut.0c00127. Epub 2020 Mar 31.
10
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?对于可切除胰腺癌是否存在标准辅助治疗？
Cancers (Basel). 2019 Oct 12;11(10):0. doi: 10.3390/cancers11101547.